Patents by Inventor Richard F. Borch
Richard F. Borch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9089605Abstract: This application describes quinone derivatives which target the redox site of Ape1/Ref1. Also included in the invention are pharmaceutical formulations containing the derivatives and therapeutic uses of the derivatives.Type: GrantFiled: September 22, 2008Date of Patent: July 28, 2015Assignee: Indiana University Research and Technology CorporationInventors: Mark R. Kelley, Richard F. Borch, Rodney L. Nyland, II
-
Publication number: 20100297113Abstract: This application describes quinone derivatives which target the redox site of Ape1/Ref1. Also included in the invention are pharmaceutical formulations containing the derivatives and therapeutic uses of the derivatives.Type: ApplicationFiled: September 22, 2008Publication date: November 25, 2010Inventors: Mark R. Kelley, Richard F. Borch, Rodney L. Nyland Ii
-
Patent number: 7304046Abstract: The invention provides a compound of formula I: wherein R1, Ra, Rb, Rc, and Rd have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds or salts. The compounds are useful for treating cancer in animals.Type: GrantFiled: December 1, 2003Date of Patent: December 4, 2007Assignee: Purdue Research FoundationInventors: Richard F. Borch, Marcy Hernick, Carolee Flader
-
Patent number: 7173020Abstract: Novel phosphoramidate derivatives of hydroxy functional or amino functional compounds, including amino acids, peptides, peptidomimetics and nucleotide analogs, are described. The compounds enable enhanced intracellular delivery of drugs as their corresponding phosphate esters or amides. Described phosphoramidate compounds exhibit antiproliferative activity. Pharmaceutical formulations are provided for treatment of cancers.Type: GrantFiled: February 8, 2005Date of Patent: February 6, 2007Assignee: Purdue Research FoundationInventors: Richard F. Borch, Hugo Garrido-Hernandez, Sandra C. Tobias
-
Patent number: 6903081Abstract: Novel phosphoramidate derivatives of hydroxy functional or amino functional compounds, including amino acids, peptides, peptidomimetics and nucleotide analogs, are described. The compounds enable enhanced intracellular delivery of drugs as their corresponding phosphate esters or amides. Described phosphoramidate compounds exhibit antiproliferative activity. Pharmaceutical formulations are provided for treatment of cancers.Type: GrantFiled: March 30, 2001Date of Patent: June 7, 2005Assignee: Purdue Research FoundationInventors: Richard F. Borch, Hugo Garrido-Hernandez, Sandra C. Tobias
-
Publication number: 20040176332Abstract: The invention provides a compound of formula I: 1Type: ApplicationFiled: December 1, 2003Publication date: September 9, 2004Applicant: Purdue Research FoundationInventors: Richard F. Borch, Marcy Hernick, Carolee Flader
-
Patent number: 6656926Abstract: The invention provides a compound of formula I: wherein R1, Ra, Rb, Rc, and Rd have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds or salts. The compounds are useful for treating cancer in animals.Type: GrantFiled: January 14, 2002Date of Patent: December 2, 2003Assignee: Purdue Research FoundationInventors: Richard F. Borch, Marcy Hernick, Carolee Flader
-
Publication number: 20030008850Abstract: The invention provides a compound of formula I: 1Type: ApplicationFiled: January 14, 2002Publication date: January 9, 2003Inventors: Richard F. Borch, Marcy Hernick, Carolee Flader
-
Publication number: 20020004594Abstract: Novel phosphoramidate derivatives of hydroxy functional or amino functional compounds, including amino acids, peptides, peptidomimetics and nucleotide analogs, are described. The compounds enable enhanced intracellular delivery of drugs as their corresponding phosphate esters or amides. Described phosphoramidate compounds exhibit antiproliferative activity. Pharmaceutical formulations are provided for treatment of cancers.Type: ApplicationFiled: March 30, 2001Publication date: January 10, 2002Inventors: Richard F. Borch, Hugo Garrido-Hernandez, Sandra C. Tobias
-
Patent number: 5955432Abstract: Compounds of the formula ##STR1## and the esters, amides, amide/esters and salts thereof, wherein YCO is .gamma.-glu or .beta.-asp;G* is phenylglycine or glycine;Z is CH.sub.2, O or S; andX is a hydrocarbon radical selected from C.sub.6 -C.sub.8 alkyl or selected aromatic groupsare useful in modulating hematopoiesis in bone marrow, mitigating the bone-marrow-destructive effects of a chemotherapeutic agent, and in potentiating the toxicity of chemotherapeutic agents.Type: GrantFiled: July 3, 1996Date of Patent: September 21, 1999Assignee: Terrapin Technologies, Inc.Inventors: Lawrence M. Kauvar, Amy S. Morgan, Matthew H. Lyttle, Richard F. Borch
-
Patent number: 5786336Abstract: A method to potentiate the effect of a chemotherapeutic agent in a tumor cell, which method comprises administering to said tumor cell, along with said chemotherapeutic agent, a potentiating amount of a compound of the formula: ##STR1## or an amide, ester or hybrid amide/ester thereof, wherein X is a hydrocarbon radical optionally substituted on any aromatic moiety contained therein; Y--CO is .gamma.-Glu or .beta.-Asp and AA.sub.C is an amino acid, preferably glycine, phenylglycine, .beta.-alanine, alanine or phenylalanine is disclosed.Similar compounds can also be used to selectively exert cytotoxicity versus target cells as compared to nontarget cells and also to elevate the production of GM progenitors in bone marrow of mammalian subjects.Type: GrantFiled: September 19, 1994Date of Patent: July 28, 1998Assignee: Terrapin Technologies, Inc.Inventors: Lawrence M. Kauvar, Matthew H. Lyttle, Amy S. Morgan, Richard F. Borch
-
Patent number: 5767086Abstract: Compounds of the formula ##STR1## and the esters, amides, amide/esters and salts thereof, wherein YCO is .gamma.-glu or .beta.-asp;G* is phenyl glycine or glycine;Z is CH.sub.2, O or S; andX is a hydrocarbon radical of 1-20 C;are useful in stimulating the differentiation of bone marrow, mitigating the bone-marrow-destructive effects of a chemotherapeutic agent, and in potentiating the toxicity of chemotherapeutic agents.Type: GrantFiled: June 7, 1995Date of Patent: June 16, 1998Assignee: Terrapin Technologies, Inc.Inventors: Lawrence M. Kauvar, Matthew H. Lyttle, Amy S. Morgan, Richard F. Borch
-
Patent number: 5472956Abstract: Cyclophosphamide analogs are provided of the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are each (C.sub.2 -C.sub.6)alkyl, substituted with a leaving group such as halo or alkylsulfonyl, R.sup.3 and R.sup.4 are the same as R.sup.1 and R.sup.2 or are H and Ar is a heteroaromatic ring and the pharmaceutically acceptable salts thereof.Type: GrantFiled: January 21, 1994Date of Patent: December 5, 1995Assignee: Research Corporation Technologies, Inc.Inventors: Richard F. Borch, James P. Schmidt
-
Patent number: 5403932Abstract: Compounds of the formula: ##STR1## which is further defined herein, possess anti-tumor activity.Type: GrantFiled: June 15, 1994Date of Patent: April 4, 1995Assignee: Research Corporation Technologies, Inc.Inventors: Richard F. Borch, Gregory W. Canute, Ronald R. Valente
-
Patent number: 5306727Abstract: Cyclophosphamide analogs are provided of the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are each (C.sub.2 -C.sub.6)alkyl, substituted with a leaving group such as halo or alkylsulfonyl, R.sup.3 and R.sup.4 are the same as R.sup.1 and R.sup.2 or are H and Ar is a heteroaromatic ring and the pharmaceutically acceptable salts thereof.Type: GrantFiled: April 30, 1993Date of Patent: April 26, 1994Assignee: Research Corporation Technologies, Inc.Inventors: Richard F. Borch, James P. Schmidt
-
Patent number: 5294430Abstract: A process for preventing or ameliorating the myelosuppression which can occur in a mammal such as a human cancer patient being treated with a platinum-free antineoplastic drug is provided, comprising administering an effective dosage of a dithiocarbamate compound to said mammal, preferably subsequent to administration of the cytotoxic drug.Type: GrantFiled: July 30, 1992Date of Patent: March 15, 1994Assignee: University of RochesterInventors: Richard F. Borch, Therese K. Schmalbach
-
Patent number: 5233031Abstract: The present invention provides a series of cytotoxic phosphoramidate analogs of 5-fluoro-2'-deoxyuridine of the general formula (I): ##STR1## wherein R.sup.1 is H, F or (C.sub.1 -C.sub.4)alkyl; R.sup.2 is CH.sub.2 CH.sub.2 X wherein X is Cl, Br, I or p-toluenesulfonyl; R.sup.3 is (C.sub.1 -C.sub.4)alkyl or CH.sub.2 CH.sub.2 X wherein X is Cl, Br, I or p-toluenesulfonyl; or wherein R.sup.2 and R.sup.3, taken together with the N atom, can be a 5- or 6-membered heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or a second ring nitrogen; R.sup.4 is H, one equivalent of a pharmaceutically-acceptable cation or (4,4,6-trimethyltetrahydro-1,3-oxazin-2-yl)ethyl, and the pharmaceutically-acceptable salts thereof.Type: GrantFiled: September 23, 1991Date of Patent: August 3, 1993Assignee: University of RochesterInventors: Richard F. Borch, Kristin M. Fries
-
Patent number: 5190929Abstract: Cyclophosphamides possessing anti-tumor activity and having the formula ##STR1## and salts thereof; wherein R is lower alkyl, aryl, aryl-lower alkyl or a nitrogen, sulfur or oxygen containing heterocyclic or heterocyclic lower alkyl, andR' is hydrogen, hydroxy or OOH with the proviso that when R' is hydrogen, R is other than methyl or phenyl and when R' is hydroxy, R is other than methyl.Type: GrantFiled: May 25, 1988Date of Patent: March 2, 1993Assignee: Research Corporation Technologies, Inc.Inventors: Richard F. Borch, Gregory W. Canute
-
Patent number: 5187193Abstract: A process is provided for obtaining one or more bone marrow cell growth factors having granulocyte/macrophage progenitor cell colony stimulating activity, said process comprising: (a) adding to the culture medium of an in vitro, established bone marrow culture a growth factor-stimulating amount of a dithiocarbamate; (b) separating the said dithiocarbamate from the in vitro treated bone marrow culture, adding fresh culture medium to said in vitro treated bone marrow culture, and permitting the concentration of said growth factor or factors to increase in said fresh culture medium; and (c) isolating said growth factor or factors from said fresh culture medium.Type: GrantFiled: March 21, 1991Date of Patent: February 16, 1993Assignee: University of RochesterInventors: Richard F. Borch, Therese K. Schmalbach
-
Patent number: 5169765Abstract: A process is provided for obtaining one or more bone marrow cell growth factors having granulocyte/macrophage progenitor cell colony stimulating activity, said process comprising: (a) adding to the culture medium of an in vitro, established bone marrow culture a growth factor-stimulating amount of a dithiocarbamate; (b) separating the said dithiocarbamate from the in vitro treated bone marrow culture, adding fresh culture medium to said in vitro treated bone marrow culture, and permitting the concentration of said growth factor or factors to increase in said fresh culture medium; and (c) isolating said growth factor or factors from said fresh culture medium.Type: GrantFiled: September 21, 1990Date of Patent: December 8, 1992Assignee: University of RochesterInventors: Richard F. Borch, Therese K. Schmalbach